Evidence map›Paper›PMID 31385227›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2019

Evolution of older patients diagnosed with early breast cancer in Spain between 1998 and 2001 included in El Alamo III project.

Mª D Torregrosa, M J Escudero, I Paredero, E Carrasco, B Bermejo, J Gavila, J García-Saenz, A Santaballa, P Martínez, A Llombart and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Expert consensus to optimize the treatment of elderly patients with luminal metastatic breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Mª D TorregrosaMedical Oncology Department, Hospital Universitario Dr. Peset, Avda Gaspar Aguilar 90, 46017, Valencia, Spain. marilotorre@gmail.com.ORCID http://orcid.org/0000-0002-1285-1131
M J EscuderoGEICAM, Spanish Breast Cancer Group, Madrid, Spain.
I ParederoMedical Oncology Department, Hospital Universitario Dr. Peset, Avda Gaspar Aguilar 90, 46017, Valencia, Spain.ORCID http://orcid.org/0000-0003-3618-8685
E CarrascoGEICAM, Spanish Breast Cancer Group, Madrid, Spain.
B BermejoGEICAM, Spanish Breast Cancer Group, Madrid, Spain.
J GavilaGEICAM, Spanish Breast Cancer Group, Madrid, Spain.
J García-SaenzGEICAM, Spanish Breast Cancer Group, Madrid, Spain.
A SantaballaGEICAM, Spanish Breast Cancer Group, Madrid, Spain.
P MartínezGEICAM, Spanish Breast Cancer Group, Madrid, Spain.
A LlombartGEICAM, Spanish Breast Cancer Group, Madrid, Spain.
R AndrésGEICAM, Spanish Breast Cancer Group, Madrid, Spain.
N BatistaGEICAM, Spanish Breast Cancer Group, Madrid, Spain.
A FernándezGEICAM, Spanish Breast Cancer Group, Madrid, Spain.
A AntónGEICAM, Spanish Breast Cancer Group, Madrid, Spain.
M SeguíGEICAM, Spanish Breast Cancer Group, Madrid, Spain.
S GonzalezGEICAM, Spanish Breast Cancer Group, Madrid, Spain.
A RuizGEICAM, Spanish Breast Cancer Group, Madrid, Spain.
GEICAM, the Spanish Breast Cancer Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAn increase in the number of cancer cases is expected in the near future. Breast cancer (BC) mortality rates increase with age even when adjusted for other variables. Here we analyzed BC disease-free survival (BCDFS) and BC specific survival (BCSS) in the El Alamo III BC registry of GEICAM Spanish Breast Cancer Group. MATERIALS AND

methodsEl Alamo III is a retrospective registry of BC patients diagnosed between 1998 and 2001. Patients with stage I-III invasive BC of age groups 55-64 years (y), 70-74 years and ≥ 75 years were included. Patients and tumors characteristics, treatments and recurrences and deaths were analyzed.

results4343 patients were included within the following age intervals: 2288 (55-64 years), 960 (70-74 years), and 1095 (≥ 75 years). Older patients (≥ 70 years) were diagnosed with more advanced tumors (stage III) than younger patients (21.5% versus 13.4%, p < 0.0001). Mastectomies were performed more on older patients and they received less chemotherapy than younger patients (66.6% versus 43.1%, p < 0.00001 and 30.8% versus 71.6%, p < 0.0001, respectively). With a median follow-up of 5.9 years, 17.7% patients had BCDFS events in the younger group and 19.8% in the older group (p < 0.0001). A decrease in BCSS was also observed in older patients, either when analyzing patients ≥ 70y (p < 0.0001) and when differentiating by the two older groups (p < 0.0001).

conclusionsOur study suggests that older BC patients have worse outcomes what can be a consequence of receiving inadequate adjuvant treatments. Specific trials for these patients are warranted to allow us to treat them with the same scientific rigor than younger patients.

Indexed as

AgedAged, 80 and overAge FactorsAntineoplastic AgentsBreast NeoplasmsCancer SurvivorsCause of DeathChemotherapy, AdjuvantDisease-Free SurvivalFemaleHumansMastectomyMiddle AgedNeoplasm Recurrence, LocalRegistriesSpainAntineoplastic AgentsAdjuvant treatmentEarly breast cancerOlder patientsSurvivalUndertreatment

Identifiers

PMID31385227

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.